Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
NeoGenomics: Q4 Earnings Snapshot
NeoGenomics: Q4 Earnings Snapshot
Associated Press Finance
Tue, February 17, 2026 at 9:26 PM GMT+9 1 min read
In this article:
NEO
+1.88%
FORT MYERS, Fla. (AP) — FORT MYERS, Fla. (AP) — NeoGenomics Inc. (NEO) on Tuesday reported a loss of $9.9 million in its fourth quarter.
The Fort Myers, Florida-based company said it had a loss of 8 cents per share. Earnings, adjusted for stock option expense and amortization costs, came to 6 cents per share.
The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 4 cents per share.
The operator of cancer-focused testing laboratories posted revenue of $190.2 million in the period, also surpassing Street forecasts. Five analysts surveyed by Zacks expected $188.5 million.
For the year, the company reported a loss of $108 million, or 84 cents per share. Revenue was reported as $727.3 million.
NeoGenomics expects full-year revenue in the range of $793 million to $801 million.
This story was generated by Automated Insights () using data from Zacks Investment Research. Access a Zacks stock report on NEO at
Terms and Privacy Policy
Privacy Dashboard
More Info